Author Bio
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.
Follow @BiologyFool
Investors can get an early stake in Humacyte, the biotech developing human acellular vessels, by buying shares in
Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC), the special acquisition company (SPAC) that plans to merge with Humacyte. In this video from
Motley Fool Live,
Feb.
22, Fool.com Contributors Brian Orelli and Keith Speights discuss Humacyte s prospects and whether it s more appropriate for a portfolio or a watch list.
Brian Orelli: Moving onto Humacyte, the company is going public through a merger with a special acquisition company (SPAC) called Alpha Healthcare Acquisition. Humacyte is developing a technique to take donor tissue and develop them into blood vessels that can then be used for a variety of uses, including something like dialysis or peripheral a
Looking to ride the SPAC train to go public? Do this first, Raleigh attorneys say bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Share:
The four-day trading week saw no weakness in SPAC deal announcements or headlines, all of which we followed on Benzinga s SPACS Attack show.
Here is a look back at the deals announced, some new SPACs to watch and top headlines.
SPAC Deals: There were eight announced SPAC deals during the week. The results were mixed as we saw some strong pops on deals and several of the names end their announcement day trading down.
Satellite company BlackSky announced a merger with
Osprey Technology Acquisition Corp (NYSE: SFTW). The deal included financial backing from Peter Thiel. BlackSky uses artificial intelligence and machine learning with its observation satellites. The company has five satellites in commercial operation, with plans to add nine more in 2021.
Key partnership with Fresenius
Humacyte was founded in 2004, and the Biotechnology Center provided it a $150,000 Small Business Research Loan in 2006.
Since then Humacyte has raised nearly $480 million, including a $150 million equity investment from Fresenius Medical Care, the world’s leading provider of products and services for patients with renal diseases and for surgical care centers.
“Humacyte is a world-class regenerative medicine company developing bioengineered tissues to treat unmet medical needs,” said Vivian Doelling, Ph.D., NCBiotech’s vice president of Emerging Company Development. “The company has been a trailblazer in these advanced and readily available technologies. It’s one of the best examples of North Carolina-based ingenuity and medical advancement.”
Human tissue developer Humacyte agrees to SPAC merger to go public reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.